[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyy7bgwC37_9s5KVOBQBy9mw6IA-u5ZP6TVyCm5eG61E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"University of Missouri-Columbia",[4],356,false,76,8,37761,33,252,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Obesity",22,{"name":18,"count":19},"Healthy",13,{"name":21,"count":22},"Insomnia",10,{"name":24,"count":25},"Insulin Resistance",9,{"name":27,"count":9},"Metabolic Syndrome",{"name":29,"count":30},"Type 2 Diabetes",7,{"name":32,"count":30},"Aging",{"name":34,"count":35},"Vasodilation",6,[37,42,47,52,57,62,67,72,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04085913","Exparel Injection Effect on Postoperative Opioid Usage","2024-06-06","Lidocaine Epinephrine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04444869","Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer","2025-06","Cisplatin",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05386914","This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults","2025-09-19","Sirolimus",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06374758","Accelerated ART Initiation for PWHIV Who Are Out of Care","2026-05-01","bictegravir\u002Femtricitabine\u002Ftenofovir alafenamide 50\u002F200\u002F25 mg",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06399952","Baker Gordon Syndrome Natural History Study","2026-05-05","Whole Genome Sequencing",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06985654","The Effect of Preoperative Intravenous Fluid Bolus on Post-induction Hypotension in Elective Cystoscopies.","2026-06","Lactated Ringers",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04436731","Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity","2026-06-30","Phenylephrine",{"nctId":73,"briefTitle":74,"date":70,"intervention":75},"NCT05219799","Sex Disparities in Hypoxic Vasodilation and Impact of Obesity","Propranolol Hydrochloride",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06417177","Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia","2026-07","Propranolol",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT03713424","An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction","2026-08-31","Clavulanic Acid",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,160,199,225,251,269,287,319,337,355,379,397,419,447,473,493,517,541,589,616,638,660,716,734,752,770,788,806,824,847,865,883,913,940,982,1030,1069,1097,1119,1151,1186,1208,1226,1251,1277,1295,1319,1337,1363,1381,1409,1427,1445,1472,1490,1508,1535,1553,1578,1603,1621,1639,1664,1691,1709,1727,1770,1796,1822,1847,1881,1907,1925,1943,1969,1987,2011,2029,2055,2079,2106,2131,2149,2174,2198,2222,2240,2264,2289,2313,2337,2360,2385,2403,2427,2450,2476,2494,2517,2542,2568,2597,2638,2660,2685,2703,2727,2751,2775,2799,2817,2835,2860,2884,2906,2930,2953,2978,3001,3019,3043,3061,3084,3109,3135,3158,3176,3199,3223],{"intervention":95,"totalTrials":96,"cells":97},"saline 0.9%",4,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":158},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":150,"soonestReadout":136},[109,121,131,143],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT04644796","A Randomized Trial of Exparel vs Saline in Opioid Reduction of Pain Management Following Lumbar Spine Surgeries.","COMPLETED",[91],"2022-06-13","2021-02-10",34,[118],"Lumbar Spine Degeneration",[95,120],"Liposomal bupivacaine",{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":79,"start":127,"enrollment":100,"conditions":128,"interventions":130},"NCT05408923","Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery","WITHDRAWN",[91],"2025-07","2022-07",[118,129],"Cervical Spine Degeneration",[95],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT04182997","Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy","RECRUITING",[91],"2026-10","2019-11-21",200,[140],"Lumbar Disc Herniation",[142,95],"Dexamethasone",{"nctId":144,"briefTitle":145,"status":146,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":154},"NCT06951191","Intrauterine Device Insertion Pain Management","TERMINATED",[91],"2026-04-15","2025-06-23",1,[152,153],"IUD Insertion Pain","IUD Insertion",[155,156,157],"Benzocaine 20%","Lidocaine 2%","Saline 0.9%",{"trials":159,"activeCount":100},[],{"intervention":161,"totalTrials":162,"cells":163},"N-acetylcysteine",2,{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":197},{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":100},[168],{"nctId":169,"briefTitle":170,"status":124,"phases":171,"primaryCompletion":172,"completion":172,"start":172,"enrollment":100,"conditions":173,"interventions":179},"NCT05908513","NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM",[88],"2021-10-15",[174,175,176,177,178],"Atherosclerosis of Artery","Peripheral Artery Disease","Diabetes Mellitus","Inflammation","Oxidative Stress",[161],{"trials":181,"activeCount":100},[],{"trials":183,"activeCount":100},[],{"trials":185,"activeCount":150,"soonestReadout":190},[186],{"nctId":187,"briefTitle":188,"status":134,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT03652753","Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)",[91],"2026-12","2019-01-01",30,[194],"Pilon Fracture",[161,196],"Saline",{"trials":198,"activeCount":100},[],{"intervention":200,"totalTrials":150,"cells":201},"Methadone-dexmedetomidine-ketamine combination",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":223},{"trials":203,"activeCount":100},[],{"trials":205,"activeCount":100},[],{"trials":207,"activeCount":100},[],{"trials":209,"activeCount":100},[],{"trials":211,"activeCount":150,"soonestReadout":190},[212],{"nctId":213,"briefTitle":214,"status":215,"phases":216,"primaryCompletion":190,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT07365800","The MDK Study: Using a Combination of Methadone-dexmedetomidine-ketamine for Postoperative Pain Control in Patients Undergoing Complex Spine Surgeries.","NOT_YET_RECRUITING",[91],"2027-06","2026-03-02",248,[221],"Spine Surgery",[200],{"trials":224,"activeCount":100},[],{"intervention":226,"totalTrials":150,"cells":227},"Hibiclens",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":249},{"trials":229,"activeCount":100},[],{"trials":231,"activeCount":100},[],{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":150,"soonestReadout":190},[238],{"nctId":239,"briefTitle":240,"status":134,"phases":241,"primaryCompletion":190,"completion":190,"start":242,"enrollment":243,"conditions":244,"interventions":247},"NCT05401292","Skin Preparation for Elective Foot and Ankle Surgery",[91],"2022-02-15",100,[245,246],"Microbial Colonization","Foot and Ankle Disorders",[226,248],"Isopropyl Alcohol 70% Topical Application Solution",{"trials":250,"activeCount":100},[],{"intervention":248,"totalTrials":150,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":100},[],{"trials":258,"activeCount":100},[],{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":150,"soonestReadout":190},[263],{"nctId":239,"briefTitle":240,"status":134,"phases":264,"primaryCompletion":190,"completion":190,"start":242,"enrollment":243,"conditions":265,"interventions":266},[91],[245,246],[226,248],{"trials":268,"activeCount":100},[],{"intervention":196,"totalTrials":150,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":285},{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":100},[],{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":150,"soonestReadout":190},[281],{"nctId":187,"briefTitle":188,"status":134,"phases":282,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":283,"interventions":284},[91],[194],[161,196],{"trials":286,"activeCount":100},[],{"intervention":288,"totalTrials":150,"cells":289},"Amoxicillin\u002Fclavulanate",{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":296,"PHASE4":298,"NA":317},{"trials":291,"activeCount":100},[],{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":150,"soonestReadout":304},[300],{"nctId":301,"briefTitle":302,"status":134,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":314},"NCT05846399","CAT BITE Antibiotic Prophylaxis for the Hand\u002FForearm (CATBITE)",[91],"2027-07-01","2027-08-01","2023-09-07",72,[309,310,311,312,313],"Cat Bite","Hand Injuries","Arm Injury","Infection, Bacterial","Anti-bacterial Agents",[288,315,316],"Ciprofloxacin","Clindamycin",{"trials":318,"activeCount":100},[],{"intervention":315,"totalTrials":150,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":100},[],{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":100},[],{"trials":330,"activeCount":150,"soonestReadout":304},[331],{"nctId":301,"briefTitle":302,"status":134,"phases":332,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":333,"interventions":334},[91],[309,310,311,312,313],[288,315,316],{"trials":336,"activeCount":100},[],{"intervention":316,"totalTrials":150,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":353},{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":150,"soonestReadout":304},[349],{"nctId":301,"briefTitle":302,"status":134,"phases":350,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":351,"interventions":352},[91],[309,310,311,312,313],[288,315,316],{"trials":354,"activeCount":100},[],{"intervention":56,"totalTrials":150,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":377},{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"trials":362,"activeCount":100},[],{"trials":364,"activeCount":100},[],{"trials":366,"activeCount":150,"soonestReadout":55},[367],{"nctId":53,"briefTitle":54,"status":134,"phases":368,"primaryCompletion":55,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":376},[91],"2026-11-01","2024-04-29",120,[373,374,375],"HIV Infections","ART","Noncompliance, Patient",[56],{"trials":378,"activeCount":100},[],{"intervention":142,"totalTrials":150,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":395},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":150,"soonestReadout":136},[391],{"nctId":132,"briefTitle":133,"status":134,"phases":392,"primaryCompletion":136,"completion":136,"start":137,"enrollment":138,"conditions":393,"interventions":394},[91],[140],[142,95],{"trials":396,"activeCount":100},[],{"intervention":66,"totalTrials":150,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":417},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":150,"soonestReadout":65},[409],{"nctId":63,"briefTitle":64,"status":410,"phases":411,"primaryCompletion":65,"completion":190,"start":412,"enrollment":243,"conditions":413,"interventions":416},"ENROLLING_BY_INVITATION",[91],"2025-07-14",[414,415],"Postinduction Hypotension","Hypotension During Surgery",[66],{"trials":418,"activeCount":100},[],{"intervention":420,"totalTrials":150,"cells":421},"GLP-1 receptor agonist",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":428,"PHASE4":430,"NA":445},{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":100},[],{"trials":431,"activeCount":150,"soonestReadout":436},[432],{"nctId":433,"briefTitle":434,"status":134,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":444},"NCT06132477","Impact GLP-1 Agonists Following Bariatric",[91],"2028-07","2030-07","2024-02-01",150,[441,27,176,442,443],"Morbid Obesity","Hypertension","Obstructive Sleep Apnea of Adult",[420],{"trials":446,"activeCount":100},[],{"intervention":448,"totalTrials":150,"cells":449},"Empagliflozin 10 MG",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":456,"PHASE4":469,"NA":471},{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":150,"soonestReadout":462},[458],{"nctId":459,"briefTitle":460,"status":134,"phases":461,"primaryCompletion":462,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":468},"NCT06506422","Empagliflozin Reversal of Arterial StiffnEss in Aging",[89,90],"2028-10-31","2029-02-28","2024-08-18",80,[32,467],"Arterial Stiffness",[448],{"trials":470,"activeCount":100},[],{"trials":472,"activeCount":100},[],{"intervention":85,"totalTrials":150,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":476,"activeCount":100},[],{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":150,"soonestReadout":84},[481],{"nctId":82,"briefTitle":83,"status":134,"phases":482,"primaryCompletion":84,"completion":84,"start":483,"enrollment":192,"conditions":484,"interventions":486},[89],"2019-03-26",[485],"Tobacco Use Disorder",[85],{"trials":488,"activeCount":100},[],{"trials":490,"activeCount":100},[],{"trials":492,"activeCount":100},[],{"intervention":46,"totalTrials":150,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":150,"soonestReadout":45},[501],{"nctId":43,"briefTitle":44,"status":134,"phases":502,"primaryCompletion":45,"completion":65,"start":503,"enrollment":504,"conditions":505,"interventions":510},[89],"2020-09-28",28,[506,507,508,509],"Cancer of the Head and Neck","Oropharynx Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Throat Carcinoma",[46],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":100},[],{"trials":516,"activeCount":100},[],{"intervention":51,"totalTrials":150,"cells":518},{"EARLY_PHASE1":519,"PHASE1":521,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":520,"activeCount":100},[],{"trials":522,"activeCount":150,"soonestReadout":50},[523],{"nctId":48,"briefTitle":49,"status":524,"phases":525,"primaryCompletion":50,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":532},"ACTIVE_NOT_RECRUITING",[88],"2027-12","2023-03-02",205,[530,531],"Genetic Predisposition to Disease","Healthy Volunteers",[51],{"trials":534,"activeCount":100},[],{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"intervention":542,"totalTrials":543,"cells":544},"Norepinephrine",3,{"EARLY_PHASE1":545,"PHASE1":579,"PHASE2":581,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":546,"activeCount":543,"soonestReadout":70},[547,556,563],{"nctId":68,"briefTitle":69,"status":524,"phases":548,"primaryCompletion":70,"completion":70,"start":549,"enrollment":550,"conditions":551,"interventions":553},[87],"2020-12-09",104,[15,18,552,34],"Vasoconstriction",[71,554,555,542],"Dexmedetomidine","Phentolamine",{"nctId":73,"briefTitle":74,"status":134,"phases":557,"primaryCompletion":70,"completion":70,"start":558,"enrollment":307,"conditions":559,"interventions":560},[87],"2023-03-14",[15,34,18],[75,561,562,542],"Isoproterenol","Phentolamine Mesylate",{"nctId":564,"briefTitle":565,"status":134,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":575},"NCT06520982","Early Neurovascular Adaptations in Aging Women",[87],"2027-06-30","2028-06-30","2024-09-20",64,[572,573,32,574],"Women","Sympathetic Nervous System","Blood Flow",[542,561,576,577,578],"Acetylcholine","Nitroprusside","Estrogen",{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":100},[],{"intervention":75,"totalTrials":162,"cells":590},{"EARLY_PHASE1":591,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":614},{"trials":592,"activeCount":162,"soonestReadout":70},[593,602],{"nctId":594,"briefTitle":595,"status":134,"phases":596,"primaryCompletion":190,"completion":190,"start":597,"enrollment":598,"conditions":599,"interventions":601},"NCT06787066","Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms",[87],"2025-07-10",75,[600],"Menopause",[75,555],{"nctId":73,"briefTitle":74,"status":134,"phases":603,"primaryCompletion":70,"completion":70,"start":558,"enrollment":307,"conditions":604,"interventions":605},[87],[15,34,18],[75,561,562,542],{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":100},[],{"trials":615,"activeCount":100},[],{"intervention":555,"totalTrials":162,"cells":617},{"EARLY_PHASE1":618,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":619,"activeCount":162,"soonestReadout":70},[620,624],{"nctId":594,"briefTitle":595,"status":134,"phases":621,"primaryCompletion":190,"completion":190,"start":597,"enrollment":598,"conditions":622,"interventions":623},[87],[600],[75,555],{"nctId":68,"briefTitle":69,"status":524,"phases":625,"primaryCompletion":70,"completion":70,"start":549,"enrollment":550,"conditions":626,"interventions":627},[87],[15,18,552,34],[71,554,555,542],{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":100},[],{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"intervention":561,"totalTrials":162,"cells":639},{"EARLY_PHASE1":640,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":641,"activeCount":162,"soonestReadout":70},[642,646],{"nctId":73,"briefTitle":74,"status":134,"phases":643,"primaryCompletion":70,"completion":70,"start":558,"enrollment":307,"conditions":644,"interventions":645},[87],[15,34,18],[75,561,562,542],{"nctId":564,"briefTitle":565,"status":134,"phases":647,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":648,"interventions":649},[87],[572,573,32,574],[542,561,576,577,578],{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":100},[],{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"intervention":80,"totalTrials":661,"cells":662},5,{"EARLY_PHASE1":663,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":664,"activeCount":162,"soonestReadout":79},[665,675,683],{"nctId":666,"briefTitle":667,"status":112,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT02871349","Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response",[87],"2020-08","2016-08",69,[673],"Autism Spectrum Disorder",[80],{"nctId":676,"briefTitle":677,"status":134,"phases":678,"primaryCompletion":190,"completion":526,"start":679,"enrollment":192,"conditions":680,"interventions":682},"NCT06066710","Propranolol in Primary Progressive Aphasia",[87],"2025-01-13",[681],"Aphasia, Primary Progressive",[80],{"nctId":77,"briefTitle":78,"status":134,"phases":684,"primaryCompletion":79,"completion":79,"start":685,"enrollment":598,"conditions":686,"interventions":688},[87],"2024-06-03",[32,600,687,34],"Hypoxia",[80,689],"Gemtesa",{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[700,708],{"nctId":701,"briefTitle":702,"status":124,"phases":703,"primaryCompletion":704,"completion":704,"start":704,"enrollment":100,"conditions":705,"interventions":707},"NCT02414451","Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response",[92],"2016-09",[706],"Autism",[80],{"nctId":709,"briefTitle":710,"status":112,"phases":711,"primaryCompletion":712,"completion":712,"start":713,"enrollment":22,"conditions":714,"interventions":715},"NCT02428205","Combined Effects of Early Behavioral Intervention and Propranolol on ASD",[92],"2022-11-01","2015-04",[706],[80],{"intervention":71,"totalTrials":150,"cells":717},{"EARLY_PHASE1":718,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":719,"activeCount":150,"soonestReadout":70},[720],{"nctId":68,"briefTitle":69,"status":524,"phases":721,"primaryCompletion":70,"completion":70,"start":549,"enrollment":550,"conditions":722,"interventions":723},[87],[15,18,552,34],[71,554,555,542],{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[],{"trials":731,"activeCount":100},[],{"trials":733,"activeCount":100},[],{"intervention":562,"totalTrials":150,"cells":735},{"EARLY_PHASE1":736,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":737,"activeCount":150,"soonestReadout":70},[738],{"nctId":73,"briefTitle":74,"status":134,"phases":739,"primaryCompletion":70,"completion":70,"start":558,"enrollment":307,"conditions":740,"interventions":741},[87],[15,34,18],[75,561,562,542],{"trials":743,"activeCount":100},[],{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":100},[],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"intervention":689,"totalTrials":150,"cells":753},{"EARLY_PHASE1":754,"PHASE1":760,"PHASE2":762,"PHASE3":764,"PHASE4":766,"NA":768},{"trials":755,"activeCount":150,"soonestReadout":79},[756],{"nctId":77,"briefTitle":78,"status":134,"phases":757,"primaryCompletion":79,"completion":79,"start":685,"enrollment":598,"conditions":758,"interventions":759},[87],[32,600,687,34],[80,689],{"trials":761,"activeCount":100},[],{"trials":763,"activeCount":100},[],{"trials":765,"activeCount":100},[],{"trials":767,"activeCount":100},[],{"trials":769,"activeCount":100},[],{"intervention":576,"totalTrials":150,"cells":771},{"EARLY_PHASE1":772,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":786},{"trials":773,"activeCount":150,"soonestReadout":567},[774],{"nctId":564,"briefTitle":565,"status":134,"phases":775,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":776,"interventions":777},[87],[572,573,32,574],[542,561,576,577,578],{"trials":779,"activeCount":100},[],{"trials":781,"activeCount":100},[],{"trials":783,"activeCount":100},[],{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":100},[],{"intervention":577,"totalTrials":150,"cells":789},{"EARLY_PHASE1":790,"PHASE1":796,"PHASE2":798,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":791,"activeCount":150,"soonestReadout":567},[792],{"nctId":564,"briefTitle":565,"status":134,"phases":793,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":794,"interventions":795},[87],[572,573,32,574],[542,561,576,577,578],{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[],{"intervention":578,"totalTrials":150,"cells":807},{"EARLY_PHASE1":808,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":809,"activeCount":150,"soonestReadout":567},[810],{"nctId":564,"briefTitle":565,"status":134,"phases":811,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":812,"interventions":813},[87],[572,573,32,574],[542,561,576,577,578],{"trials":815,"activeCount":100},[],{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[],{"intervention":41,"totalTrials":150,"cells":825},{"EARLY_PHASE1":826,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":827,"activeCount":150,"soonestReadout":40},[828],{"nctId":38,"briefTitle":39,"status":410,"phases":829,"primaryCompletion":40,"completion":126,"start":830,"enrollment":243,"conditions":831,"interventions":834},[87],"2019-09-30",[832,833],"Thyroid","Parathyroid Adenoma",[41,835,836],"Bupivacaine Hydrochloride-EPINEPHrine","Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine",{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"trials":844,"activeCount":100},[],{"trials":846,"activeCount":100},[],{"intervention":835,"totalTrials":150,"cells":848},{"EARLY_PHASE1":849,"PHASE1":855,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":850,"activeCount":150,"soonestReadout":40},[851],{"nctId":38,"briefTitle":39,"status":410,"phases":852,"primaryCompletion":40,"completion":126,"start":830,"enrollment":243,"conditions":853,"interventions":854},[87],[832,833],[41,835,836],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":100},[],{"intervention":836,"totalTrials":150,"cells":866},{"EARLY_PHASE1":867,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":868,"activeCount":150,"soonestReadout":40},[869],{"nctId":38,"briefTitle":39,"status":410,"phases":870,"primaryCompletion":40,"completion":126,"start":830,"enrollment":243,"conditions":871,"interventions":872},[87],[832,833],[41,835,836],{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":100},[],{"trials":878,"activeCount":100},[],{"trials":880,"activeCount":100},[],{"trials":882,"activeCount":100},[],{"intervention":554,"totalTrials":162,"cells":884},{"EARLY_PHASE1":885,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":886,"activeCount":150,"soonestReadout":70},[887],{"nctId":68,"briefTitle":69,"status":524,"phases":888,"primaryCompletion":70,"completion":70,"start":549,"enrollment":550,"conditions":889,"interventions":890},[87],[15,18,552,34],[71,554,555,542],{"trials":892,"activeCount":100},[],{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[901],{"nctId":902,"briefTitle":903,"status":112,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":912},"NCT00839605","Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation",[],"2009-11","2009-03",25,[909,910,911],"Esophageal Cancer","Lung Cancer","Chest Wall Disorders",[554],{"intervention":61,"totalTrials":150,"cells":914},{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":916,"activeCount":100},[],{"trials":918,"activeCount":100},[],{"trials":920,"activeCount":100},[],{"trials":922,"activeCount":100},[],{"trials":924,"activeCount":100},[],{"trials":926,"activeCount":150,"soonestReadout":60},[927],{"nctId":58,"briefTitle":59,"status":134,"phases":928,"primaryCompletion":60,"completion":60,"start":929,"enrollment":930,"conditions":931,"interventions":939},[],"2024-04-30",50,[932,933,934,935,936,937,938],"Rare Diseases","Autism or Autistic Traits","Development Delay","SYT-SSX Fusion Protein Expression","Sleep Disorder","Epilepsy, Generalized","Motor Delay",[61],{"intervention":941,"totalTrials":543,"cells":942},"Sitagliptin",{"EARLY_PHASE1":943,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":980},{"trials":944,"activeCount":100},[945],{"nctId":946,"briefTitle":947,"status":124,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":100,"conditions":951,"interventions":952},"NCT02444364","Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus",[87],"2016-01","2015-05",[29],[941],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[961,971],{"nctId":962,"briefTitle":963,"status":146,"phases":964,"primaryCompletion":949,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT02048904","Use of Sitagliptin to Decrease Microalbuminuria",[91],"2016-06","2014-01",142,[29,969],"Microalbuminuria",[941],{"nctId":972,"briefTitle":973,"status":124,"phases":974,"primaryCompletion":975,"completion":949,"start":976,"enrollment":100,"conditions":977,"interventions":979},"NCT02263677","Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI",[91],"2015-12","2014-03",[29,978],"Non-alcoholic Fatty Liver Disease",[941],{"trials":981,"activeCount":100},[],{"intervention":983,"totalTrials":543,"cells":984},"Normal Saline",{"EARLY_PHASE1":985,"PHASE1":999,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1028},{"trials":986,"activeCount":100},[987],{"nctId":988,"briefTitle":989,"status":112,"phases":990,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":996},"NCT04541303","Topical Tranexamic Acid Use on Granulating Wounds Following Mohs Micrographic Surgery",[87],"2021-12-30","2020-10-08",124,[995],"Postoperative Wound Haemorrhage",[997,998],"Tranexamic acid","normal saline",{"trials":1000,"activeCount":100},[1001],{"nctId":1002,"briefTitle":1003,"status":124,"phases":1004,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":100,"conditions":1007,"interventions":1009},"NCT03677310","Effects of 3% Sodium Chloride on Post-operative Dysphagia Following Anterior Cervical Spine Surgery",[88],"2019-11","2018-04",[1008],"Dysphagia",[1010,983],"3% Sodium Chloride",{"trials":1012,"activeCount":100},[],{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[1017],{"nctId":1018,"briefTitle":1019,"status":112,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":191,"enrollment":1022,"conditions":1023,"interventions":1025},"NCT03564886","Hyperosmolar Saline Irrigation Fluid in Arthroscopic Knee Surgery",[91],"2019-09-05",48,[1024],"Arthroscopic Knee Surgery",[1026,1027],"Hyperosmolar Saline","Normal saline",{"trials":1029,"activeCount":100},[],{"intervention":1031,"totalTrials":162,"cells":1032},"Rocuronium",{"EARLY_PHASE1":1033,"PHASE1":1035,"PHASE2":1037,"PHASE3":1039,"PHASE4":1041,"NA":1067},{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[1043,1053],{"nctId":1044,"briefTitle":1045,"status":112,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1052},"NCT02703909","Surgical Conditions During Laparoscopic Bariatric Surgery",[91],"2017-05-30","2017-10","2016-05",144,[441],[1031],{"nctId":1054,"briefTitle":1055,"status":112,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1060,"interventions":1063},"NCT05887375","Sugammadex vs Neostigmine\u002FGlycopyrrolate on Urinary Retention After Spine Surgery",[91],"2026-01-15","2023-08-03",118,[221,1061,1062],"Reversal of Neuromuscular Blockade","Urinary Retention Postoperative",[1064,1065,1066,1031],"Sugammadex","Neostigmine","Glycopyrrolate",{"trials":1068,"activeCount":100},[],{"intervention":1064,"totalTrials":162,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1077,"PHASE4":1079,"NA":1095},{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":100},[],{"trials":1076,"activeCount":100},[],{"trials":1078,"activeCount":100},[],{"trials":1080,"activeCount":100},[1081,1085],{"nctId":1054,"briefTitle":1055,"status":112,"phases":1082,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1083,"interventions":1084},[91],[221,1061,1062],[1064,1065,1066,1031],{"nctId":1086,"briefTitle":1087,"status":112,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":1047,"enrollment":1091,"conditions":1092,"interventions":1093},"NCT03112993","Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery",[91],"2018-08-13","2018-08-14",40,[221],[1094,1065],"sugammadex",{"trials":1096,"activeCount":100},[],{"intervention":1065,"totalTrials":162,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1103,"PHASE3":1105,"PHASE4":1107,"NA":1117},{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"trials":1106,"activeCount":100},[],{"trials":1108,"activeCount":100},[1109,1113],{"nctId":1054,"briefTitle":1055,"status":112,"phases":1110,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1111,"interventions":1112},[91],[221,1061,1062],[1064,1065,1066,1031],{"nctId":1086,"briefTitle":1087,"status":112,"phases":1114,"primaryCompletion":1089,"completion":1090,"start":1047,"enrollment":1091,"conditions":1115,"interventions":1116},[91],[221],[1094,1065],{"trials":1118,"activeCount":100},[],{"intervention":1120,"totalTrials":162,"cells":1121},"Memantine",{"EARLY_PHASE1":1122,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1137,"NA":1149},{"trials":1123,"activeCount":100},[1124],{"nctId":1125,"briefTitle":1126,"status":112,"phases":1127,"primaryCompletion":1128,"completion":1128,"start":965,"enrollment":22,"conditions":1129,"interventions":1130},"NCT02811627","Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy",[87],"2021-04",[673],[1120],{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[],{"trials":1138,"activeCount":100},[1139],{"nctId":1140,"briefTitle":1141,"status":146,"phases":1142,"primaryCompletion":1143,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1148},"NCT00462228","Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury",[91],"2010-12","2007-04",11,[1147],"Traumatic Brain Injury",[1120],{"trials":1150,"activeCount":100},[],{"intervention":1152,"totalTrials":162,"cells":1153},"Acetaminophen",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1162,"NA":1184},{"trials":1155,"activeCount":100},[],{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[],{"trials":1163,"activeCount":100},[1164,1174],{"nctId":1165,"briefTitle":1166,"status":112,"phases":1167,"primaryCompletion":1168,"completion":1168,"start":966,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT02076321","The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study",[91],"2016-11",102,[1171],"Fractures",[1152,1173],"Ibuprofen",{"nctId":1175,"briefTitle":1176,"status":146,"phases":1177,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT03749616","Effect of NSAID Use on Pain and Opioid Consumption Following Distal Radius Fracture",[91],"2022-03-24","2019-01-02",32,[1182],"Distal Radius Fracture",[1173,1152],{"trials":1185,"activeCount":100},[],{"intervention":1173,"totalTrials":162,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1206},{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":100},[1198,1202],{"nctId":1165,"briefTitle":1166,"status":112,"phases":1199,"primaryCompletion":1168,"completion":1168,"start":966,"enrollment":1169,"conditions":1200,"interventions":1201},[91],[1171],[1152,1173],{"nctId":1175,"briefTitle":1176,"status":146,"phases":1203,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1204,"interventions":1205},[91],[1182],[1173,1152],{"trials":1207,"activeCount":100},[],{"intervention":120,"totalTrials":150,"cells":1209},{"EARLY_PHASE1":1210,"PHASE1":1212,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1224},{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[],{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[1220],{"nctId":110,"briefTitle":111,"status":112,"phases":1221,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":1222,"interventions":1223},[91],[118],[95,120],{"trials":1225,"activeCount":100},[],{"intervention":1227,"totalTrials":150,"cells":1228},"Benzoyl Peroxide Topical",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1235,"PHASE4":1237,"NA":1249},{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[],{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[1239],{"nctId":1240,"briefTitle":1241,"status":124,"phases":1242,"primaryCompletion":1243,"completion":1244,"start":1245,"enrollment":100,"conditions":1246,"interventions":1248},"NCT05676411","Benzoyl Peroxide and Electrocautery Skin Incision to Eradicate Cutibacterium Acnes",[91],"2025-07-30","2025-08-30","2024-06-01",[1247],"Prosthetic-joint Infection",[1227],{"trials":1250,"activeCount":100},[],{"intervention":1252,"totalTrials":150,"cells":1253},"Bupivacaine",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1275},{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[1264],{"nctId":1265,"briefTitle":1266,"status":112,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1274},"NCT04362566","Bupivacaine for Post-operative Pain in Mohs",[91],"2021-09-30","2020-07-30",174,[1272,1273],"Pain, Postoperative","Narcotic Use",[1252],{"trials":1276,"activeCount":100},[],{"intervention":1066,"totalTrials":150,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1293},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[1289],{"nctId":1054,"briefTitle":1055,"status":112,"phases":1290,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1291,"interventions":1292},[91],[221,1061,1062],[1064,1065,1066,1031],{"trials":1294,"activeCount":100},[],{"intervention":1296,"totalTrials":150,"cells":1297},"Allogenix Plus",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1317},{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[1308],{"nctId":1309,"briefTitle":1310,"status":124,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":100,"conditions":1314,"interventions":1316},"NCT01006148","Comparison of a Bone Product to Bone Dust in Ossification of Small Calvarial Defects.",[91],"2010-08","2009-10",[1315],"Metopic Craniosynostosis",[1296],{"trials":1318,"activeCount":100},[],{"intervention":1026,"totalTrials":150,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1335},{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[1331],{"nctId":1018,"briefTitle":1019,"status":112,"phases":1332,"primaryCompletion":1021,"completion":1021,"start":191,"enrollment":1022,"conditions":1333,"interventions":1334},[91],[1024],[1026,1027],{"trials":1336,"activeCount":100},[],{"intervention":1338,"totalTrials":150,"cells":1339},"Omeprazole",{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1361},{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"trials":1345,"activeCount":100},[],{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[1350],{"nctId":1351,"briefTitle":1352,"status":112,"phases":1353,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":1091,"conditions":1357,"interventions":1359},"NCT00557349","Ulcer Prevention Study in Post Gastric Bypass Patients",[91],"2007-11","2008-03","2006-11",[1358],"Marginal Ulcers",[1338,1360],"Famotidine",{"trials":1362,"activeCount":100},[],{"intervention":1360,"totalTrials":150,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1379},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[],{"trials":1374,"activeCount":100},[1375],{"nctId":1351,"briefTitle":1352,"status":112,"phases":1376,"primaryCompletion":1354,"completion":1355,"start":1356,"enrollment":1091,"conditions":1377,"interventions":1378},[91],[1358],[1338,1360],{"trials":1380,"activeCount":100},[],{"intervention":1382,"totalTrials":150,"cells":1383},"Triamcinolone Acetonide 40mg\u002FmL",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1407},{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[1394],{"nctId":1395,"briefTitle":1396,"status":146,"phases":1397,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":1402,"interventions":1404},"NCT04002037","Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis",[91],"2022-05-19","2023-01-01","2019-06-25",95,[1403],"Trigger Finger",[1382,1405,1406],"Triamcinolone Acetonide 10mg\u002FmL","Dexamethasone 4 mg\u002Fml",{"trials":1408,"activeCount":100},[],{"intervention":1405,"totalTrials":150,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1425},{"trials":1412,"activeCount":100},[],{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[1421],{"nctId":1395,"briefTitle":1396,"status":146,"phases":1422,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":1423,"interventions":1424},[91],[1403],[1382,1405,1406],{"trials":1426,"activeCount":100},[],{"intervention":1406,"totalTrials":150,"cells":1428},{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1443},{"trials":1430,"activeCount":100},[],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[1439],{"nctId":1395,"briefTitle":1396,"status":146,"phases":1440,"primaryCompletion":1398,"completion":1399,"start":1400,"enrollment":1401,"conditions":1441,"interventions":1442},[91],[1403],[1382,1405,1406],{"trials":1444,"activeCount":100},[],{"intervention":1446,"totalTrials":150,"cells":1447},"Methylnaltrexone Bromide 150 mg Oral",{"EARLY_PHASE1":1448,"PHASE1":1450,"PHASE2":1452,"PHASE3":1454,"PHASE4":1456,"NA":1470},{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[1458],{"nctId":1459,"briefTitle":1460,"status":112,"phases":1461,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1465,"interventions":1467},"NCT03523520","Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation",[91],"2023-03-31","2020-12-23",15,[1466],"Constipation Drug Induced",[1446,1468,1469],"Methylnaltrexone Bromide 12 MG\u002F0.6 ML Subcutaneous Solution [RELISTOR]_#1","Naloxegol 25 MG Oral",{"trials":1471,"activeCount":100},[],{"intervention":1468,"totalTrials":150,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1482,"NA":1488},{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[1484],{"nctId":1459,"briefTitle":1460,"status":112,"phases":1485,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1486,"interventions":1487},[91],[1466],[1446,1468,1469],{"trials":1489,"activeCount":100},[],{"intervention":1469,"totalTrials":150,"cells":1491},{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1506},{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[1502],{"nctId":1459,"briefTitle":1460,"status":112,"phases":1503,"primaryCompletion":1462,"completion":1462,"start":1463,"enrollment":1464,"conditions":1504,"interventions":1505},[91],[1466],[1446,1468,1469],{"trials":1507,"activeCount":100},[],{"intervention":1509,"totalTrials":150,"cells":1510},"Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1533},{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[1521],{"nctId":1522,"briefTitle":1523,"status":146,"phases":1524,"primaryCompletion":1525,"completion":1525,"start":1526,"enrollment":1527,"conditions":1528,"interventions":1531},"NCT03824808","Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery",[91],"2020-03-26","2019-02-26",21,[1529,1530],"Kidney Cancer","Prostate Cancer",[1509,1532],"0.9% Sodium Chloride",{"trials":1534,"activeCount":100},[],{"intervention":1532,"totalTrials":150,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1551},{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[1547],{"nctId":1522,"briefTitle":1523,"status":146,"phases":1548,"primaryCompletion":1525,"completion":1525,"start":1526,"enrollment":1527,"conditions":1549,"interventions":1550},[91],[1529,1530],[1509,1532],{"trials":1552,"activeCount":100},[],{"intervention":1554,"totalTrials":150,"cells":1555},"Miacalcin Calcitonin Salmon Nasal Spray",{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1576},{"trials":1557,"activeCount":100},[],{"trials":1559,"activeCount":100},[],{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[1566],{"nctId":1567,"briefTitle":1568,"status":112,"phases":1569,"primaryCompletion":1570,"completion":1571,"start":1572,"enrollment":1527,"conditions":1573,"interventions":1575},"NCT03812991","The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries",[91],"2022-09-30","2023-02-28","2019-07-01",[1574],"Pelvic Ring Fractures",[1554],{"trials":1577,"activeCount":100},[],{"intervention":1579,"totalTrials":150,"cells":1580},"Nitrofurantoin",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1601},{"trials":1582,"activeCount":100},[],{"trials":1584,"activeCount":100},[],{"trials":1586,"activeCount":100},[],{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[1591],{"nctId":1592,"briefTitle":1593,"status":112,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1600},"NCT00734968","Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence",[91],"2010-05","2008-05",161,[1599],"Stress Incontinence",[1579],{"trials":1602,"activeCount":100},[],{"intervention":155,"totalTrials":150,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1613,"NA":1619},{"trials":1606,"activeCount":100},[],{"trials":1608,"activeCount":100},[],{"trials":1610,"activeCount":100},[],{"trials":1612,"activeCount":100},[],{"trials":1614,"activeCount":100},[1615],{"nctId":144,"briefTitle":145,"status":146,"phases":1616,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":1617,"interventions":1618},[91],[152,153],[155,156,157],{"trials":1620,"activeCount":100},[],{"intervention":156,"totalTrials":150,"cells":1622},{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1637},{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[],{"trials":1632,"activeCount":100},[1633],{"nctId":144,"briefTitle":145,"status":146,"phases":1634,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":1635,"interventions":1636},[91],[152,153],[155,156,157],{"trials":1638,"activeCount":100},[],{"intervention":1640,"totalTrials":150,"cells":1641},"Ketorolac",{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1650,"NA":1662},{"trials":1643,"activeCount":100},[],{"trials":1645,"activeCount":100},[],{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[1652],{"nctId":1653,"briefTitle":1654,"status":146,"phases":1655,"primaryCompletion":1656,"completion":1656,"start":1657,"enrollment":1658,"conditions":1659,"interventions":1661},"NCT03464461","Dosing of Ketorolac in the Emergency Department",[91],"2024-05-30","2018-05-01",289,[1660],"Acute Pain",[1640],{"trials":1663,"activeCount":100},[],{"intervention":1665,"totalTrials":150,"cells":1666},"Botulinum Toxin Type A",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1689},{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[1677],{"nctId":1678,"briefTitle":1679,"status":146,"phases":1680,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":9,"conditions":1684,"interventions":1686},"NCT01045694","Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint",[91],"2012-08","2015-10","2011-03",[1685],"Arthritis Multiple Joint",[1665,1687,1688],"Steroid - Triamcinolone Acetonide","Lidocaine",{"trials":1690,"activeCount":100},[],{"intervention":1687,"totalTrials":150,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1707},{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[],{"trials":1702,"activeCount":100},[1703],{"nctId":1678,"briefTitle":1679,"status":146,"phases":1704,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":9,"conditions":1705,"interventions":1706},[91],[1685],[1665,1687,1688],{"trials":1708,"activeCount":100},[],{"intervention":1688,"totalTrials":150,"cells":1710},{"EARLY_PHASE1":1711,"PHASE1":1713,"PHASE2":1715,"PHASE3":1717,"PHASE4":1719,"NA":1725},{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[1721],{"nctId":1678,"briefTitle":1679,"status":146,"phases":1722,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":9,"conditions":1723,"interventions":1724},[91],[1685],[1665,1687,1688],{"trials":1726,"activeCount":100},[],{"intervention":1728,"totalTrials":162,"cells":1729},"Pregabalin 300mg",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1766,"NA":1768},{"trials":1731,"activeCount":100},[],{"trials":1733,"activeCount":100},[],{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[1738,1750],{"nctId":1739,"briefTitle":1740,"status":112,"phases":1741,"primaryCompletion":1742,"completion":1743,"start":1744,"enrollment":1059,"conditions":1745,"interventions":1749},"NCT04122196","Perioperative Pregabalin in Ureteroscopy",[89,90],"2023-07-01","2024-07-01","2020-06-01",[1746,1272,1747,1748],"Kidney Stone","Addiction","Opioid Use",[1728],{"nctId":1751,"briefTitle":1752,"status":112,"phases":1753,"primaryCompletion":1754,"completion":1755,"start":1756,"enrollment":22,"conditions":1757,"interventions":1765},"NCT03927781","Perioperative Pregabalin in Ureteroscopy: a Pilot",[90],"2019-10-17","2020-10-17","2019-04-01",[1758,1759,1760,1272,1761,1762,1763,1764],"Nephrolithiasis","Urolithiasis","Perioperative\u002FPostoperative Complications","Pain, Acute","Anesthesia","Urologic Diseases","Anesthesia Morbidity",[1728],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"intervention":1771,"totalTrials":150,"cells":1772},"Amiloride Pill",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1792,"NA":1794},{"trials":1774,"activeCount":100},[],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[1781],{"nctId":1782,"briefTitle":1783,"status":112,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT03837626","ENAC Blockade and Arterial Stiffness",[89,90],"2024-10-05","2025-04-30","2019-07-15",137,[1790,24],"Overweight and Obesity",[1771],{"trials":1793,"activeCount":100},[],{"trials":1795,"activeCount":100},[],{"intervention":1797,"totalTrials":150,"cells":1798},"Prednisone",{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1805,"PHASE4":1818,"NA":1820},{"trials":1800,"activeCount":100},[],{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[1807],{"nctId":1808,"briefTitle":1809,"status":112,"phases":1810,"primaryCompletion":1811,"completion":1812,"start":1813,"enrollment":22,"conditions":1814,"interventions":1817},"NCT03508440","Intratympanic Steroid for Bell's Palsy",[89,90],"2022-11-22","2023-06-01","2018-01-31",[1815,1816],"Bell's Palsy","Facial Nerve Paresis",[1797],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"intervention":1823,"totalTrials":150,"cells":1824},"Dornase Alfa Inhalation Solution",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1843,"NA":1845},{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":112,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":192,"conditions":1839,"interventions":1842},"NCT04402970","Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)",[90],"2020-12-31","2020-06-19",[1840,1841],"SARS-CoV 2","ARDS",[1823],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":100},[],{"intervention":1848,"totalTrials":162,"cells":1849},"Allopurinol",{"EARLY_PHASE1":1850,"PHASE1":1862,"PHASE2":1864,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1851,"activeCount":100},[1852],{"nctId":1853,"briefTitle":1854,"status":124,"phases":1855,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":100,"conditions":1859,"interventions":1861},"NCT03076684","Gender Differences in the Metabolic Effects of Uric Acid",[87],"2018-12","2019-03-13","2017-03-03",[1860],"Hyperuricemia",[1848],{"trials":1863,"activeCount":100},[],{"trials":1865,"activeCount":100},[1866],{"nctId":1867,"briefTitle":1868,"status":112,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":116,"conditions":1872,"interventions":1874},"NCT03648996","Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid",[89],"2022-03-10","2018-11-01",[1873,1860],"Diabetes Mellitus, Type 2",[1848],{"trials":1876,"activeCount":100},[],{"trials":1878,"activeCount":100},[],{"trials":1880,"activeCount":100},[],{"intervention":1882,"totalTrials":150,"cells":1883},"Low Dose",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1885,"activeCount":100},[],{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":100},[1890],{"nctId":1891,"briefTitle":1892,"status":112,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1897,"interventions":1898},"NCT00549523","A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults",[88,89],"2012-01","2008-04",133,[373],[1882,1899,1900],"Mid Dose","High Dose",{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[],{"intervention":1899,"totalTrials":150,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[1915],{"nctId":1891,"briefTitle":1892,"status":112,"phases":1916,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1917,"interventions":1918},[88,89],[373],[1882,1899,1900],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[],{"intervention":1900,"totalTrials":150,"cells":1926},{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[1933],{"nctId":1891,"briefTitle":1892,"status":112,"phases":1934,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":1896,"conditions":1935,"interventions":1936},[88,89],[373],[1882,1899,1900],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"intervention":1944,"totalTrials":150,"cells":1945},"Triamcinolone Acetonide 40 mg\u002Fml Inj, Susp",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1947,"activeCount":100},[],{"trials":1949,"activeCount":100},[],{"trials":1951,"activeCount":100},[1952],{"nctId":1953,"briefTitle":1954,"status":146,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1958,"conditions":1959,"interventions":1961},"NCT05657496","Biological Response to Platelet-rich Plasma and Corticosteroid Injections",[88,89],"2025-06-18","2022-12-28",23,[1960],"Knee Osteoarthritis",[1944,1962],"Platelet-rich plasma Inj",{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[],{"trials":1968,"activeCount":100},[],{"intervention":1962,"totalTrials":150,"cells":1970},{"EARLY_PHASE1":1971,"PHASE1":1973,"PHASE2":1975,"PHASE3":1981,"PHASE4":1983,"NA":1985},{"trials":1972,"activeCount":100},[],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[1977],{"nctId":1953,"briefTitle":1954,"status":146,"phases":1978,"primaryCompletion":1956,"completion":1956,"start":1957,"enrollment":1958,"conditions":1979,"interventions":1980},[88,89],[1960],[1944,1962],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[],{"intervention":1988,"totalTrials":150,"cells":1989},"Euphrasia-based homeopathic therapy",{"EARLY_PHASE1":1990,"PHASE1":1992,"PHASE2":1994,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1991,"activeCount":100},[],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[1996],{"nctId":1997,"briefTitle":1998,"status":146,"phases":1999,"primaryCompletion":1312,"completion":1312,"start":2000,"enrollment":30,"conditions":2001,"interventions":2003},"NCT01072526","Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease",[89],"2007-12",[2002],"Dry Eye Syndromes",[1988,2004],"Cyclosporin solution",{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"intervention":2004,"totalTrials":150,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":100},[],{"trials":2016,"activeCount":100},[],{"trials":2018,"activeCount":100},[2019],{"nctId":1997,"briefTitle":1998,"status":146,"phases":2020,"primaryCompletion":1312,"completion":1312,"start":2000,"enrollment":30,"conditions":2021,"interventions":2022},[89],[2002],[1988,2004],{"trials":2024,"activeCount":100},[],{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"intervention":2030,"totalTrials":150,"cells":2031},"zinc-green tea extract-ascorbic acid",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2033,"activeCount":100},[],{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[2038],{"nctId":2039,"briefTitle":2040,"status":146,"phases":2041,"primaryCompletion":2042,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2048},"NCT04898023","Zinc and Green Tea Extract for Community Respiratory Viral Infections",[89],"2023-10-31","2023-12-20","2022-09-21",17,[2047],"Respiratory Viral Infection",[2030],{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"intervention":2056,"totalTrials":150,"cells":2057},"Elderberry Juice",{"EARLY_PHASE1":2058,"PHASE1":2060,"PHASE2":2062,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2059,"activeCount":100},[],{"trials":2061,"activeCount":100},[],{"trials":2063,"activeCount":100},[2064],{"nctId":2065,"briefTitle":2066,"status":112,"phases":2067,"primaryCompletion":2068,"completion":2068,"start":704,"enrollment":2069,"conditions":2070,"interventions":2072},"NCT02414607","Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment",[88,89],"2019-12",24,[2071],"Mild Cognitive Impairment",[2056],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"intervention":2080,"totalTrials":150,"cells":2081},"Oral Riboflavin",{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"trials":2087,"activeCount":100},[2088],{"nctId":2089,"briefTitle":2090,"status":2091,"phases":2092,"primaryCompletion":2093,"completion":2094,"start":2095,"enrollment":243,"conditions":2096,"interventions":2099},"NCT03552016","Evaluation of Progression of Myopia in Children Treated With Vitamin B2 and Outdoor Sunlight Exposure","SUSPENDED",[89],"2029-10-10","2030-10-10","2018-10-10",[2097,2098],"Axial Myopia","Refractive Errors",[2080],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[],{"intervention":2107,"totalTrials":150,"cells":2108},"Omega-3 Ethyl Esters 4 g",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2125,"PHASE4":2127,"NA":2129},{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[2115],{"nctId":2116,"briefTitle":2117,"status":146,"phases":2118,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":150,"conditions":2121,"interventions":2123},"NCT06434948","The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery",[89],"2026-04-29","2026-03-03",[2122],"Postoperative Delirium",[2107,2124],"Omega-3 Ethyl Esters 2 g",{"trials":2126,"activeCount":100},[],{"trials":2128,"activeCount":100},[],{"trials":2130,"activeCount":100},[],{"intervention":2124,"totalTrials":150,"cells":2132},{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2143,"PHASE4":2145,"NA":2147},{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[2139],{"nctId":2116,"briefTitle":2117,"status":146,"phases":2140,"primaryCompletion":2119,"completion":2119,"start":2120,"enrollment":150,"conditions":2141,"interventions":2142},[89],[2122],[2107,2124],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"intervention":2150,"totalTrials":150,"cells":2151},"3-V Bioscience-2640",{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2168,"PHASE4":2170,"NA":2172},{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":100},[],{"trials":2157,"activeCount":100},[2158],{"nctId":2159,"briefTitle":2160,"status":112,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":2165,"conditions":2166,"interventions":2167},"NCT02948569","Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome",[88,89],"2017-12-18","2019-01-30","2017-02-01",12,[27],[2150],{"trials":2169,"activeCount":100},[],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[],{"intervention":2175,"totalTrials":150,"cells":2176},"Zanamivir",{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[2183],{"nctId":2184,"briefTitle":2185,"status":112,"phases":2186,"primaryCompletion":2187,"completion":2187,"start":2188,"enrollment":2189,"conditions":2190,"interventions":2191},"NCT04867707","Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes",[89],"2024-10-18","2021-07-14",14,[1873],[2175],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"intervention":2199,"totalTrials":150,"cells":2200},"Infusion of opioid growth factor",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2202,"activeCount":100},[],{"trials":2204,"activeCount":100},[2205],{"nctId":2206,"briefTitle":2207,"status":112,"phases":2208,"primaryCompletion":2209,"completion":2209,"start":2210,"enrollment":2189,"conditions":2211,"interventions":2213},"NCT00706576","Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor",[88],"2013-07","2008-06",[2212],"Hepatocellular Cancer",[2199],{"trials":2215,"activeCount":100},[],{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[],{"intervention":1010,"totalTrials":150,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[2228],{"nctId":1002,"briefTitle":1003,"status":124,"phases":2229,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":100,"conditions":2230,"interventions":2231},[88],[1008],[1010,983],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"intervention":2241,"totalTrials":150,"cells":2242},"PolyMVA",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2256,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[2247],{"nctId":2248,"briefTitle":2249,"status":112,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2165,"conditions":2253,"interventions":2255},"NCT04557410","Open Label Study: Treatment of ALS Fatigue With PolyMVA",[88],"2021-05-25","2020-09-23",[2254],"Amyotrophic Lateral Sclerosis",[2241],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[],{"trials":2263,"activeCount":100},[],{"intervention":2265,"totalTrials":150,"cells":2266},"tDCS and CO-OP Group",{"EARLY_PHASE1":2267,"PHASE1":2269,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2268,"activeCount":100},[],{"trials":2270,"activeCount":100},[2271],{"nctId":2272,"briefTitle":2273,"status":112,"phases":2274,"primaryCompletion":2275,"completion":2276,"start":2277,"enrollment":9,"conditions":2278,"interventions":2280},"NCT04617548","tDCS and CO-OP in Chronic Stroke",[88],"2021-12-31","2022-01-01","2020-01-01",[2279],"Chronic Stroke",[2265],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"trials":2286,"activeCount":100},[],{"trials":2288,"activeCount":100},[],{"intervention":2290,"totalTrials":150,"cells":2291},"Lessertia Fructescens",{"EARLY_PHASE1":2292,"PHASE1":2294,"PHASE2":2305,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[2296],{"nctId":2297,"briefTitle":2298,"status":112,"phases":2299,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":907,"conditions":2302,"interventions":2304},"NCT00376415","A Safety Study of Lessertia Frutescens in Adults.",[88],"2005-01","2004-09",[2303],"Drug Safety",[2290],{"trials":2306,"activeCount":100},[],{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"trials":2312,"activeCount":100},[],{"intervention":2314,"totalTrials":150,"cells":2315},"NAVI mapping with Indocyanine green",{"EARLY_PHASE1":2316,"PHASE1":2327,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2317,"activeCount":100},[2318],{"nctId":2319,"briefTitle":2320,"status":112,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":1145,"conditions":2324,"interventions":2326},"NCT03430934","Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor",[87],"2019-08-01","2018-07-01",[2325],"Skin Cancer",[2314],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"intervention":2338,"totalTrials":150,"cells":2339},"Insulin",{"EARLY_PHASE1":2340,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2341,"activeCount":100},[2342],{"nctId":2343,"briefTitle":2344,"status":112,"phases":2345,"primaryCompletion":2346,"completion":2346,"start":2347,"enrollment":504,"conditions":2348,"interventions":2349},"NCT05244694","Impact of Insulin on Sympathetic Nervous System-mediated Peripheral Vasoconstriction",[87],"2021-06-25","2020-08-06",[552,18,24],[2338],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[],{"intervention":2361,"totalTrials":150,"cells":2362},"Alcohol: Oral administration",{"EARLY_PHASE1":2363,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2364,"activeCount":100},[2365],{"nctId":2366,"briefTitle":2367,"status":146,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":543,"conditions":2371,"interventions":2373},"NCT04299373","Surgical Weight Loss and Alcohol Perception",[87],"2022-09-09","2020-02-10",[2372],"Bariatric Surgery Candidate",[2361,2374],"Alcohol: Intravenous administration",{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[],{"trials":2382,"activeCount":100},[],{"trials":2384,"activeCount":100},[],{"intervention":2374,"totalTrials":150,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":100},[2389],{"nctId":2366,"briefTitle":2367,"status":146,"phases":2390,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":543,"conditions":2391,"interventions":2392},[87],[2372],[2361,2374],{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":100},[],{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"intervention":2404,"totalTrials":150,"cells":2405},"Propranolol Pill",{"EARLY_PHASE1":2406,"PHASE1":2417,"PHASE2":2419,"PHASE3":2421,"PHASE4":2423,"NA":2425},{"trials":2407,"activeCount":100},[2408],{"nctId":2409,"briefTitle":2410,"status":112,"phases":2411,"primaryCompletion":2412,"completion":2412,"start":2413,"enrollment":2414,"conditions":2415,"interventions":2416},"NCT05256069","Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia",[87],"2025-07-31","2023-04-26",31,[34,687],[2404],{"trials":2418,"activeCount":100},[],{"trials":2420,"activeCount":100},[],{"trials":2422,"activeCount":100},[],{"trials":2424,"activeCount":100},[],{"trials":2426,"activeCount":100},[],{"intervention":2428,"totalTrials":150,"cells":2429},"Hyperinsulinemic, euglycemic",{"EARLY_PHASE1":2430,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2431,"activeCount":100},[2432],{"nctId":2433,"briefTitle":2434,"status":124,"phases":2435,"primaryCompletion":2436,"completion":2436,"start":2436,"enrollment":100,"conditions":2437,"interventions":2439},"NCT05518422","Role of Endothelin-1 Modulating Insulin-stimulated Blood Flow and Sympathetic Nervous System Activity in Obesity",[87],"2024-02",[24,2438,15],"Autonomic Dysfunction",[2428],{"trials":2441,"activeCount":100},[],{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":100},[],{"trials":2449,"activeCount":100},[],{"intervention":2451,"totalTrials":150,"cells":2452},"Enteric coated Devil's Claw",{"EARLY_PHASE1":2453,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2454,"activeCount":100},[2455],{"nctId":2456,"briefTitle":2457,"status":124,"phases":2458,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":100,"conditions":2462,"interventions":2464},"NCT03641248","Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract",[87],"2021-07-31","2021-08-31","2021-05-01",[2463],"Osteoarthritis, Knee",[2451,2465],"Non-enteric coated Devil's Claw",{"trials":2467,"activeCount":100},[],{"trials":2469,"activeCount":100},[],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"trials":2475,"activeCount":100},[],{"intervention":2465,"totalTrials":150,"cells":2477},{"EARLY_PHASE1":2478,"PHASE1":2484,"PHASE2":2486,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2479,"activeCount":100},[2480],{"nctId":2456,"briefTitle":2457,"status":124,"phases":2481,"primaryCompletion":2459,"completion":2460,"start":2461,"enrollment":100,"conditions":2482,"interventions":2483},[87],[2463],[2451,2465],{"trials":2485,"activeCount":100},[],{"trials":2487,"activeCount":100},[],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"intervention":2495,"totalTrials":150,"cells":2496},"Human insulin",{"EARLY_PHASE1":2497,"PHASE1":2507,"PHASE2":2509,"PHASE3":2511,"PHASE4":2513,"NA":2515},{"trials":2498,"activeCount":100},[2499],{"nctId":2500,"briefTitle":2501,"status":2091,"phases":2502,"primaryCompletion":217,"completion":217,"start":2503,"enrollment":2504,"conditions":2505,"interventions":2506},"NCT05153395","Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation",[87],"2021-12-01",65,[18,34,24,2438,15],[2495],{"trials":2508,"activeCount":100},[],{"trials":2510,"activeCount":100},[],{"trials":2512,"activeCount":100},[],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"intervention":2518,"totalTrials":150,"cells":2519},"Human Papillomavirus Vaccine",{"EARLY_PHASE1":2520,"PHASE1":2532,"PHASE2":2534,"PHASE3":2536,"PHASE4":2538,"NA":2540},{"trials":2521,"activeCount":100},[2522],{"nctId":2523,"briefTitle":2524,"status":124,"phases":2525,"primaryCompletion":2526,"completion":2527,"start":2528,"enrollment":100,"conditions":2529,"interventions":2531},"NCT00829608","Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis",[87],"2009-12","2010-06","2009-01",[2530],"Recurrent Respiratory Papillomatosis",[2518],{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[],{"trials":2537,"activeCount":100},[],{"trials":2539,"activeCount":100},[],{"trials":2541,"activeCount":100},[],{"intervention":2543,"totalTrials":150,"cells":2544},"Oral Bosentan 62.5 mg",{"EARLY_PHASE1":2545,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2546,"activeCount":100},[2547],{"nctId":2548,"briefTitle":2549,"status":112,"phases":2550,"primaryCompletion":2551,"completion":2552,"start":2553,"enrollment":2554,"conditions":2555,"interventions":2557},"NCT05146089","Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences",[87],"2018-09-08","2021-04-12","2016-12-20",54,[2556,18,552,34],"Sleep Apnea",[2543],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[],{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[],{"intervention":997,"totalTrials":162,"cells":2569},{"EARLY_PHASE1":2570,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2584},{"trials":2571,"activeCount":100},[2572],{"nctId":988,"briefTitle":989,"status":112,"phases":2573,"primaryCompletion":991,"completion":991,"start":992,"enrollment":993,"conditions":2574,"interventions":2575},[87],[995],[997,998],{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":100},[],{"trials":2585,"activeCount":100},[2586],{"nctId":2587,"briefTitle":2588,"status":112,"phases":2589,"primaryCompletion":2590,"completion":2590,"start":2591,"enrollment":2592,"conditions":2593,"interventions":2595},"NCT02051686","Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid",[92],"2016-12","2013-06",88,[2594],"Acetabulum Fractures",[2596],"Tranexamic Acid",{"intervention":2598,"totalTrials":162,"cells":2599},"propofol",{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2601,"activeCount":100},[],{"trials":2603,"activeCount":100},[],{"trials":2605,"activeCount":100},[],{"trials":2607,"activeCount":100},[],{"trials":2609,"activeCount":100},[],{"trials":2611,"activeCount":100},[2612,2625],{"nctId":2613,"briefTitle":2614,"status":146,"phases":2615,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2622},"NCT02604459","Does Optimized General Anesthesia Care Reduce Postoperative Delirium?",[92],"2018-02-28","2015-06-01",145,[2620,1762,2621],"Hip Fractures","Delirium",[2598,2623,2624],"fentanyl","sevoflurane",{"nctId":2626,"briefTitle":2627,"status":146,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2632,"interventions":2634},"NCT01126957","Combined Ketamine\u002FPropofol for Emergency Department Procedural Sedation",[92],"2010-03","2007-05",107,[2633],"Procedural Sedation and Analgesia",[2635,2636,2637],"Ketamine","Fentanyl","Propofol",{"intervention":2623,"totalTrials":162,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[2652,2656],{"nctId":2613,"briefTitle":2614,"status":146,"phases":2653,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2654,"interventions":2655},[92],[2620,1762,2621],[2598,2623,2624],{"nctId":2626,"briefTitle":2627,"status":146,"phases":2657,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2658,"interventions":2659},[92],[2633],[2635,2636,2637],{"intervention":2661,"totalTrials":150,"cells":2662},"Poractant alfa",{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2671,"NA":2673},{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"trials":2668,"activeCount":100},[],{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675],{"nctId":2676,"briefTitle":2677,"status":112,"phases":2678,"primaryCompletion":2679,"completion":2680,"start":2209,"enrollment":192,"conditions":2681,"interventions":2683},"NCT02834624","Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome",[92],"2015-02","2015-07",[2682],"Respiratory Distress Syndrome",[2661,2684],"calfactant",{"intervention":2684,"totalTrials":150,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[],{"trials":2698,"activeCount":100},[2699],{"nctId":2676,"briefTitle":2677,"status":112,"phases":2700,"primaryCompletion":2679,"completion":2680,"start":2209,"enrollment":192,"conditions":2701,"interventions":2702},[92],[2682],[2661,2684],{"intervention":2704,"totalTrials":150,"cells":2705},"Pantoprazole",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[2718],{"nctId":2719,"briefTitle":2720,"status":146,"phases":2721,"primaryCompletion":2722,"completion":2722,"start":2723,"enrollment":543,"conditions":2724,"interventions":2726},"NCT02235311","Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed",[92],"2015-08-17","2014-10",[2725],"Upper Gastrointestinal Bleed",[2704],{"intervention":2728,"totalTrials":150,"cells":2729},"Ferrous Sulfate",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[],{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[2742],{"nctId":2743,"briefTitle":2744,"status":146,"phases":2745,"primaryCompletion":2746,"completion":2068,"start":965,"enrollment":2747,"conditions":2748,"interventions":2750},"NCT02839096","Once Versus Twice Daily Iron Supplementation in Pregnant Women",[92],"2019-06",20,[2749],"Anemia in Pregnancy",[2728],{"intervention":2752,"totalTrials":150,"cells":2753},"Pegvaliase-Pqpz",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2755,"activeCount":100},[],{"trials":2757,"activeCount":100},[],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"trials":2765,"activeCount":100},[2766],{"nctId":2767,"briefTitle":2768,"status":112,"phases":2769,"primaryCompletion":2770,"completion":2770,"start":2771,"enrollment":35,"conditions":2772,"interventions":2774},"NCT05356377","Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU",[],"2025-07-01","2022-05-25",[2773],"Phenylketonurias",[2752],{"intervention":2776,"totalTrials":150,"cells":2777},"Arthrocentesis\u002FPRP",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2788},{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[],{"trials":2787,"activeCount":100},[],{"trials":2789,"activeCount":100},[2790],{"nctId":2791,"briefTitle":2792,"status":112,"phases":2793,"primaryCompletion":1005,"completion":1005,"start":2794,"enrollment":1145,"conditions":2795,"interventions":2797},"NCT02481869","Platelet Rich Plasma Injection in Pilon Fractures",[92],"2015-06",[2796],"Fracture",[2776,2798],"Arthrocentesis\u002FSaline",{"intervention":2798,"totalTrials":150,"cells":2800},{"EARLY_PHASE1":2801,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"trials":2808,"activeCount":100},[],{"trials":2810,"activeCount":100},[],{"trials":2812,"activeCount":100},[2813],{"nctId":2791,"briefTitle":2792,"status":112,"phases":2814,"primaryCompletion":1005,"completion":1005,"start":2794,"enrollment":1145,"conditions":2815,"interventions":2816},[92],[2796],[2776,2798],{"intervention":2624,"totalTrials":150,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2827,"NA":2829},{"trials":2820,"activeCount":100},[],{"trials":2822,"activeCount":100},[],{"trials":2824,"activeCount":100},[],{"trials":2826,"activeCount":100},[],{"trials":2828,"activeCount":100},[],{"trials":2830,"activeCount":100},[2831],{"nctId":2613,"briefTitle":2614,"status":146,"phases":2832,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2833,"interventions":2834},[92],[2620,1762,2621],[2598,2623,2624],{"intervention":2836,"totalTrials":150,"cells":2837},"cefazolin",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"trials":2845,"activeCount":100},[],{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[2850],{"nctId":2851,"briefTitle":2852,"status":112,"phases":2853,"primaryCompletion":966,"completion":966,"start":2854,"enrollment":2855,"conditions":2856,"interventions":2859},"NCT00610987","Antibiotic Prophylaxis in Orthopaedic Traumatology",[92],"2008-01",178,[2857,2858],"Fractures, Closed","Wounds and Injuries",[2836],{"intervention":2861,"totalTrials":150,"cells":2862},"The Modified Oxford Technique for Baroreflex Sensitivity",{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"trials":2870,"activeCount":100},[],{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[2875],{"nctId":2876,"briefTitle":2877,"status":146,"phases":2878,"primaryCompletion":2879,"completion":2879,"start":2880,"enrollment":162,"conditions":2881,"interventions":2883},"NCT01048125","Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy",[92],"2012-07","2009-08",[2882],"Cardiomyopathy",[2861],{"intervention":2885,"totalTrials":150,"cells":2886},"baclofen, intrathecal",{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[],{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[],{"trials":2896,"activeCount":100},[],{"trials":2898,"activeCount":100},[2899],{"nctId":2900,"briefTitle":2901,"status":124,"phases":2902,"primaryCompletion":713,"completion":713,"start":2903,"enrollment":100,"conditions":2904,"interventions":2905},"NCT01352611","Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen",[92],"2014-09",[673],[2885],{"intervention":2907,"totalTrials":150,"cells":2908},"MediHoney",{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[2921],{"nctId":2922,"briefTitle":2923,"status":146,"phases":2924,"primaryCompletion":2925,"completion":2925,"start":2926,"enrollment":19,"conditions":2927,"interventions":2929},"NCT01230489","The Efficacy of \"MediHoney\" to Facilitate Catheter Exit-Site Surgical Wound Healing",[92],"2016-11-28","2011-01",[2928],"Renal Failure",[2907],{"intervention":2931,"totalTrials":150,"cells":2932},"Simvastatin",{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[2945],{"nctId":2946,"briefTitle":2947,"status":112,"phases":2948,"primaryCompletion":2949,"completion":2949,"start":906,"enrollment":2165,"conditions":2950,"interventions":2952},"NCT01097785","Targeting Sympathetic Overactivity in Heart Failure Patients With Statins",[92],"2014-07",[2951],"Heart Failure",[2931],{"intervention":2954,"totalTrials":150,"cells":2955},"Truvada",{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2957,"activeCount":100},[],{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"trials":2965,"activeCount":100},[],{"trials":2967,"activeCount":100},[2968],{"nctId":2969,"briefTitle":2970,"status":124,"phases":2971,"primaryCompletion":2972,"completion":2972,"start":2973,"enrollment":100,"conditions":2974,"interventions":2977},"NCT02572505","Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples",[92],"2017-09-20","2015-11",[2975,2976],"HIV","Infertility",[2954],{"intervention":2979,"totalTrials":150,"cells":2980},"regional anesthesia bupivacaine",{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2987,"PHASE4":2989,"NA":2991},{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[],{"trials":2992,"activeCount":100},[2993],{"nctId":2994,"briefTitle":2995,"status":124,"phases":2996,"primaryCompletion":1048,"completion":1048,"start":1682,"enrollment":100,"conditions":2997,"interventions":2999},"NCT02674113","Regional Anesthesia in Hip Arthroscopy",[92],[2998],"Femoroacetabular Impingement",[2979,3000],"regional anesthesia placebo",{"intervention":3000,"totalTrials":150,"cells":3002},{"EARLY_PHASE1":3003,"PHASE1":3005,"PHASE2":3007,"PHASE3":3009,"PHASE4":3011,"NA":3013},{"trials":3004,"activeCount":100},[],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[],{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[3015],{"nctId":2994,"briefTitle":2995,"status":124,"phases":3016,"primaryCompletion":1048,"completion":1048,"start":1682,"enrollment":100,"conditions":3017,"interventions":3018},[92],[2998],[2979,3000],{"intervention":3020,"totalTrials":150,"cells":3021},"Dobutamine stress echo",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":100},[3034],{"nctId":3035,"briefTitle":3036,"status":112,"phases":3037,"primaryCompletion":2926,"completion":2926,"start":2210,"enrollment":3038,"conditions":3039,"interventions":3041},"NCT00998205","Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction",[92],16,[3040],"Diastolic Dysfunction",[3020,3042],"Atropine bolus",{"intervention":3042,"totalTrials":150,"cells":3044},{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3055},{"trials":3046,"activeCount":100},[],{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[3057],{"nctId":3035,"briefTitle":3036,"status":112,"phases":3058,"primaryCompletion":2926,"completion":2926,"start":2210,"enrollment":3038,"conditions":3059,"interventions":3060},[92],[3040],[3020,3042],{"intervention":3062,"totalTrials":150,"cells":3063},"Sapropterin",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[3076],{"nctId":3077,"briefTitle":3078,"status":112,"phases":3079,"primaryCompletion":1312,"completion":3080,"start":2880,"enrollment":2747,"conditions":3081,"interventions":3083},"NCT00964236","The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)",[],"2011-08",[3082],"Phenylketonuria",[3062],{"intervention":3085,"totalTrials":150,"cells":3086},"Pentoxifylline",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3097},{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[3099],{"nctId":3100,"briefTitle":3101,"status":146,"phases":3102,"primaryCompletion":1837,"completion":2552,"start":3103,"enrollment":3104,"conditions":3105,"interventions":3108},"NCT02592863","Trental for the Treatment of Vertigo\u002FDizziness\u002FImbalance",[92],"2015-01",26,[3106,3107],"Dizziness","Vertigo",[3085],{"intervention":3110,"totalTrials":150,"cells":3111},"Antibiotic",{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3122},{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[],{"trials":3119,"activeCount":100},[],{"trials":3121,"activeCount":100},[],{"trials":3123,"activeCount":100},[3124],{"nctId":3125,"briefTitle":3126,"status":112,"phases":3127,"primaryCompletion":3128,"completion":2794,"start":3129,"enrollment":3130,"conditions":3131,"interventions":3134},"NCT01561703","Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use",[92],"2013-12","2012-03",58,[3132,3133],"Snoring","Strep Throat",[3110],{"intervention":3136,"totalTrials":150,"cells":3137},"Horizant",{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3139,"activeCount":100},[],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[3150],{"nctId":3151,"briefTitle":3152,"status":112,"phases":3153,"primaryCompletion":3154,"completion":3154,"start":949,"enrollment":22,"conditions":3155,"interventions":3157},"NCT02642315","The Effect of Horizant (Gabapentin Enacarbil) on Augmentation",[92],"2019-05-06",[3156],"Restless Legs Syndrome",[3136],{"intervention":2635,"totalTrials":150,"cells":3159},{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3164,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[3172],{"nctId":2626,"briefTitle":2627,"status":146,"phases":3173,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":3174,"interventions":3175},[92],[2633],[2635,2636,2637],{"intervention":3177,"totalTrials":150,"cells":3178},"Injection with Gadolinium",{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3180,"activeCount":100},[],{"trials":3182,"activeCount":100},[],{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[3191],{"nctId":3192,"briefTitle":3193,"status":112,"phases":3194,"primaryCompletion":3195,"completion":3195,"start":713,"enrollment":2747,"conditions":3196,"interventions":3198},"NCT02217280","Dispersal Pattern for Spine Injections (Gadolinium Contrast)",[92],"2016-03",[3197],"Cervical Radiculopathy",[3177],{"intervention":3200,"totalTrials":150,"cells":3201},"Transdermal estradiol",{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3210,"NA":3212},{"trials":3203,"activeCount":100},[],{"trials":3205,"activeCount":100},[],{"trials":3207,"activeCount":100},[],{"trials":3209,"activeCount":100},[],{"trials":3211,"activeCount":100},[],{"trials":3213,"activeCount":100},[3214],{"nctId":3215,"briefTitle":3216,"status":146,"phases":3217,"primaryCompletion":3218,"completion":3218,"start":3219,"enrollment":96,"conditions":3220,"interventions":3222},"NCT01633814","Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women",[92],"2015-08","2011-09",[600,32,3221],"Blood Pressure",[3200],{"intervention":3224,"totalTrials":150,"cells":3225},"Darifenacin",{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[],{"trials":3235,"activeCount":100},[],{"trials":3237,"activeCount":100},[3238],{"nctId":3239,"briefTitle":3240,"status":146,"phases":3241,"primaryCompletion":3242,"completion":3242,"start":2880,"enrollment":543,"conditions":3243,"interventions":3246},"NCT01189071","Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain",[92],"2011-07",[3244,3245,1272],"Overactive Bladder","Renal Colic",[3224]]